Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
Martin SoubrierBruno PereiraThomas FrayssacAngelique FanMarion CoudercSandrine Malochet-GuinamandSylvain MathieuZuzana TatarAnne TournadreJean-Jacques DubostPublished in: International journal of rheumatic diseases (2017)
In real life, there was no difference in retention among the three anti-TNF agents, and 25% of patients continued them at 15 years. After failure of an anti-TNF, the switch to a non-anti-TNF biotherapy showed better retention.
Keyphrases
- rheumatoid arthritis
- rheumatoid arthritis patients
- disease activity
- end stage renal disease
- ankylosing spondylitis
- newly diagnosed
- juvenile idiopathic arthritis
- chronic kidney disease
- healthcare
- prognostic factors
- peritoneal dialysis
- physical activity
- patient reported outcomes
- ulcerative colitis
- quality improvement